Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density - Implications in tumor progression

Cancer Research

Volumn 66, Issue 16, 2006, Pages 7957-7967

  Yang, Lin ^a   Avila, Hector ^a   Wang, Heng ^a   Trevino, Jose ^a   Gallick, Gary E ^a   Kitadai, Yasuhiko ^a   Sasaki, Takamitsu ^a   Boyd, Douglas D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL CLONING; CELL DENSITY; CELL POPULATION; CELL SUBPOPULATION; CELL SURFACE; COLON CANCER; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTER; GENE EXPRESSION; LYMPH NODE METASTASIS; METASTASIS; MOUSE; NONHUMAN; OSCILLATION; PHENOTYPE; PLASTICITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TUMOR CELL; TUMOR GROWTH;

ALTERNATIVE SPLICING; CELL DIVISION; CLONE CELLS; COLONIC NEOPLASMS; DISEASE PROGRESSION; DNA PRIMERS; DNA, NEOPLASM; FLOW CYTOMETRY; HUMANS; RECEPTORS, CELL SURFACE; REGULATORY SEQUENCES, NUCLEIC ACID; TRANSCRIPTION, GENETIC;

EID: 33748053952     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3208     Document Type: Article

References (54)

1. Sharma N, Seftor RE, Seftor EA, et al. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 2002;50:189-201.
2. Sood AK, Seftor EA, Fletcher MS, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001;158:1279-88.
3. Hendrix MJ, Seftor EA, Meltzer PS, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A 2001;98:8018-23.
4. Gao C-F, Xie Q, Su Y-L, et al. Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci U S A 2005;102:10528-33.
5. Hurst RE, Kyker KD, Bonner RB, et al. Matrix-dependent plasticity of the malignant phenotype of bladder cancer cells. Anticancer Res 2003;23:3119-28.
6. Brabletz T, Jung A, Reu S, et al. Variable (1-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001;98:10356-61.
7. Aguirre-Ghiso JA, Liu D, Mignatti A, et al. Urokinase receptor and fibronectin regulate the ERK to p38 activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001;12:863-79.
8. Jechlinger M, Grunert S, Beug H. Mechanisms of epithelial plasticity and metastasis. J Mammary Gland Biol Neoplasia 2003;7:415-32.
9. r receptor protein for urokinase-type plasminogen activator. J Biol Chem 1988;263:2358-63.
10. Nestl A, Von Stein OD, Zatloukal K, et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 2001;61:1569-77.
11. Memarzedeh S, Kozak KR, Chang L, et al. Urokinase plasminogen activator receptor: prognostic biomarker for endometrial cancer. Proc Natl Acad Sci U S A 2002;99:10647-52.
12. Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 2002;62:2390-7.
13. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase. J Biol Chem 1991;266:12,752-8.
14. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-5.
15. Wei Y, Waltz DA, Rao N, et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269:32380-8.
16. Jo M, Thomas KS, O'Donnell DM, et al. Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J Biol Chem 2003;278:1642-6.
17. Liu D, Aguirre-Ghiso JA, Estrada Y, et al. EGFR is a transducer of the urokinase receptor inititiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002;1:445-57.
18. Resnati M, Pallavicini I, Wang JM, et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A 2002;99:1359-64.
19. 2-terminal domain of the urokinase receptor. FEBS Lett 1991;288:233-6.
20. Allgayer H, Wang H, Gallick GE, et al. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J Biol Chem 1999;274:18428-45.
21. Lengyel E, Wang H, Stepp E, et al. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J Biol Chem 1996;271:23176-84.
22. Wang H, Yang L, Jamaluddin MdS, et al. The Kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells. J Biol Chem 2004;279:22674-83.
23. Yan C, Jamaluddin MdS, Aggarwal BB, et al. Gene expressing profiling identifies ATF3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther 2005;4:233-41.
24. Wang H, Skibber J, Juarez J, et al. Transcriptional activation of the urokinase receptor gene in invasive colon cancer. Int J Cancer 1994;58:650-7.
25. Miller CT, Aggarwal S, Lin TK, et al. Amplification and overexpression of the dual-specificity tyrosine (Y) phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas. Cancer Res 2003;63:4136-43.
26. Hashida H, Takabayashi A, Tokuhara T, et al. Clinical significance of transmembrane 4 superfamily in colon cancer. Br J Cancer 2003;89:158-67.
27. Mazzocca A, Carloni V, Sciammetta S, et al. Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. J Hepatol 2002;37:322-30.
28. Kaklamani VG, Pasche B. Role of TGF-β in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther 2004;4:649-61.
29. Ginestra A, Monea S, Seghezzi G, et al. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 cells. J Biol Chem 1997;272:17216-22.
30. Chavakis T, Willuweit AK, Lupu F, et al. Release of soluble urokinase receptor from vascular cells. Thromb Haemost 2001;86:686-93.
31. Estreicher A, Wohlwend A, Belin D, et al. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 1989;264:1180-9.
32. Ploug M, Ronne E, Behrendt N, et al. Cellular receptor for urokinase plasminogen activator. J Biol Chem 1991;266:1926-33.
33. Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999;147:89-103.
34. Palumbo JS, Potter JM, Kaplan LS, et al. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002;62:6966-72.
35. 5-directed cell migration. J Biol Chem 1996;271:29393-9.
36. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation of stem cell properties in melanomas. Cancer Res 2005;65:9328-37.
37. Lengyel E, Wang H, Gum R, et al. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. Oncogene 1997;14:2563-73.
38. Mann B, Gelos M, Wiedow A, et al. Target genes of β-catenin-T cell factor/lymphoid-enhancer factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A 1999;96:1603-8.
39. Wyatt CA, Coon CI, Gibson JJ, et al. Potential for the 2G single nucleotide polymorphism in the promoter of matrix metalloproteinase to enhance gene expression in normal stromal cells. Cancer Res 2002;62:7200-2.
40. Blake WJ, Kaern M, Cantor CR, et al. Noise in eukaryotic gene expression. Nature 2003;422:633-7.
41. Shetty S, Kumar A, Idell S. Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol Cell Biol 1997;17:1075-83.
42. Mahoney TS, Weyrich AS, Dixon DA, et al. Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes. Proc Natl Acad Sci U S A 2001;98:10284-9.
43. Perez-Otano I, Ehlers MD. Homeostatic plasticity and NMDA receptor trafficking. Trends Neurosci 2005;28:229-38.
44. Conese M, Olson D, Blasi F. Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and α2-macroglobulin receptor. J Biol Chem 1994;269:17886-92.
45. Cubellis M, Wun T, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990;9:1079-85.
46. Nykjaer A, Conese M, Cremona O, et al. Recycling of the urokinase receptor upon internalization of the uPA: serpin complexes. EMBO J 1997;16:2610-20.
47. Montuori N, Carriero MV, Salzano S, et al. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 2002;277:46932-9.
48. Montuori N, Visconte V, Rossi G, et al. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb Haemost 2005;93:192-8.
49. Wilhelm OG, Wilhelm S, Escott GM, et al. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol 1999;180:225-35.
50. Kristensen P, Eriksen J, Blasi F, et al. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol 1992;115:1763-71.
51. Lutz V, Reuning U Kruger A, et al. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol Chem 2001;382:789-98.
52. Behrendt N, Dano K. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system. FEBS Lett 1996;393:31-6.
53. Stephens R, Nielsem HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999;91:869-74.
54. Sidenius N, Sier CFM, Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterization of uPAR fragments in vitro and in vivo. FEBS Lett 2000;475:52-6.